Australia's TGA tackles backlog of pharma applications for GMP clearance
This article was originally published in SRA
Executive Summary
Recent measures introduced by Australia's Therapeutic Goods Administration to deal with a growing backlog of applications for good manufacturing practice (GMP) clearance for medicines are having a positive impact and are helping to shorten the time it has been taking for the agency to process applications1.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.